The degradation of poloxamer 188 in buffered formulation conditions

被引:0
|
作者
Wei Chen
Siegfried Stolz
Vincent Wegbecher
Dixy Parakkattel
Christina Haeuser
Nuria Sancho Oltra
Ravuri S. K. Kishore
Steven Bond
Christian Bell
Robert Kopf
机构
[1] F. Hoffmann-La Roche AG,
关键词
Poloxamer; Degradation; Chromatography; Pharmaceutically relevant conditions; Degradants characterization; LC-MS;
D O I
10.1186/s41120-022-00055-4
中图分类号
学科分类号
摘要
Poloxamer 188 (P188) as a non-ionic surfactant is used in proteinaceous formulations to prevent protein adsorption to hydrophobic surfaces and unfolding at interfaces, preventing the formation of aggregates and particles. Its chemical intactness is crucial to the stability of drug products due to its protecting effects at interfaces. In order to identify and mitigate potential risks that might cause the degradation of P188 during the manufacturing process and storage, in the current work, the stability of P188 was investigated by forced degradation in buffered formulation conditions via oxidation and thermal stress conditions. The process of degradation was monitored through the dedicated liquid adsorption chromatography (LAC) with high sensitivity, and the degradants were characterized by high-resolution mass spectrometry. Results suggest that the vulnerability of P188 is largely related to the buffer conditions. Histidine promotes degradation in the presence of hydroxyl radicals but inhibits the degradation in the presence of H2O2 and alkyl radicals. In thermal stress conditions, histidine protects P188 from degradation at 40 °C, and activates its decay only at higher temperature, like 60 °C.
引用
收藏
相关论文
共 50 条
  • [1] Solution Stability of Poloxamer 188 Under Stress Conditions
    Wang, Tingting
    Markham, Aaron
    Thomas, Steven J.
    Wang, Ning
    Huang, Lihua
    Clemens, Matthew
    Rajagopalan, Natarajan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (03) : 1264 - 1271
  • [2] PCL/poloxamer 188 blend microsphere for paclitaxel delivery: Influence of poloxamer 188 on morphology and drug release
    Ma, Guilei
    Song, Cunxian
    JOURNAL OF APPLIED POLYMER SCIENCE, 2007, 104 (03) : 1895 - 1899
  • [3] Poloxamer 188 for Sickle Cell Disease
    Zylke, Jody
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (15): : 1524 - 1524
  • [4] POLOXAMER-188 AS VEHICLE FOR INJECTABLE DIAZEPAM
    PRANCAN, AV
    ECANOW, B
    BERNARDONI, RJ
    SADOVE, MS
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (08) : 970 - 971
  • [5] Membrane sealing by poloxamer P188.
    Lee, KYC
    Maskarinec, S
    Hannig, J
    Lee, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U345 - U345
  • [6] Effects of poloxamer 188 on traumatic brain injury
    Wu, Renqing
    Koduri, Roopa
    Cho, Michael
    Alatrash, Nagham
    Nomellini, Vanessa
    BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2024, 38
  • [7] Effects of poloxamer 188 on human PMN cells
    Harting, Matthew T.
    Jimenez, Fernando
    Kozar, Rosemary A.
    Moore, Frederick A.
    Mercer, David W.
    Hunter, Robert L.
    Cox, Charles S., Jr.
    Gonzalez, Ernest A.
    SURGERY, 2008, 144 (02) : 198 - 203
  • [8] Poloxamer 188 (P188) as a membrane resealing reagent in biomedical applications
    Moloughney, Joseph G.
    Weisleder, Noah
    Recent Patents on Biotechnology, 2012, 6 (03) : 200 - 211
  • [9] Phase behavior of poloxamer 188 in frozen aqueous solutions-Influence of processing conditions and cosolutes
    Duggirala, Naga Kiran
    Sonje, Jayesh
    Yuan, Xiaoda
    Shalaev, Evgenyi
    Suryanarayanan, Raj
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 609
  • [10] Formulation of Genistein-HP β Cyclodextrin-Poloxamer 188 Ternary Inclusion Complex: Solubility to Cytotoxicity Assessment
    Zafar, Ameeduzzafar
    Alruwaili, Nabil K.
    Imam, Syed Sarim
    Alsaidan, Omar Awad
    Alkholifi, Faisal K.
    Alharbi, Khalid Saad
    Mostafa, Ehab M.
    Alanazi, Abdullah S.
    Gilani, Sadaf Jamal
    Musa, Arafa
    Alshehri, Sultan
    Rawaf, Alenazy
    Alquraini, Ali
    PHARMACEUTICS, 2021, 13 (12)